Company Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Delayed London S.E. 09:00:22 2024-03-04 am EST 5-day change 1st Jan Change
143 GBX +4.00% Intraday chart for Arecor Therapeutics plc -1.38% -21.64%

Business Summary

Arecor Therapeutics plc is a globally focused biopharmaceutical company. The Company, through its formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver formulations of their therapeutic products. Its clinical development programs include AT247-Ultra-Rapid Acting Insulin and AT278-Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. AT278 is a concentrated formulation of rapid acting insulin that is designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. It also has Tetris Pharma portfolio.

Number of employees: 51

Sales per Business

GBP in Million2021Weight2022Weight Delta
Biotechnology
100.0 %
1 100.0 % 2 100.0 % +107.51%

Sales per region

GBP in Million2021Weight2022Weight Delta
United Kingdom
47.3 %
0 6.1 % 1 47.3 % +1,500.00%
United States
32.6 %
1 81.2 % 1 32.6 % -16.60%
Switzerland
10.0 %
-- 0 10.0 % -
India
5.6 %
-- 0 5.6 % -
Rest of Europe
4.5 %
0 6.6 % 0 4.5 % +42.11%

Managers

Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 65 18-12-31
Chief Tech/Sci/R&D Officer - 07-07-31
Corporate Officer/Principal - -
General Counsel - -
Corporate Officer/Principal - 23-04-04

Members of the board

Members of the board TitleAgeSince
Director/Board Member 78 -
Director/Board Member 66 21-04-30
Chairman 64 -
Director of Finance/CFO 65 18-12-31
Chief Executive Officer 49 -
Director/Board Member 59 17-08-31
Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 30,626,986 14,837,000 ( 48.44 %) 0 48.44 %

Shareholders

NameEquities%Valuation
Lombard Odier Asset Management (Europe) Ltd.
5.300 %
1,623,127 5.300 % 3 M p
Oxford Technology Management Ltd.
5.184 %
1,587,776 5.184 % 3 M p
Chelverton Asset Management Ltd.
4.653 %
1,425,000 4.653 % 3 M p
Unicorn Asset Management Ltd.
3.914 %
1,198,828 3.914 % 3 M p
867,738 2.833 % 2 M p
Amati Global Investors Ltd.
2.756 %
844,041 2.756 % 2 M p
Amati Global Investors Ltd. (Venture Capital)
2.721 %
833,246 2.721 % 2 M p
Canaccord Genuity Wealth Ltd.
2.063 %
631,687 2.063 % 1 M p
CRUX Asset Management Ltd.
1.812 %
554,897 1.812 % 1 M p
Calculus Capital Ltd.
1.402 %
429,474 1.402 % 907 878 p

Company contact information

Arecor Therapeutics Plc

Chesterford Research Park

CB10 1XL, Little Chesterford

+44 1223 426 060

http://www.arecor.com
address Arecor Therapeutics plc(AREC)
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW